The AKT kinase is activated in multiple myeloma tumor cells

Blood

Volumn 98, Issue 9, 2001, Pages 2853-2855

  Hsu, Jung Hsin ^a   Shi, Yijiang ^b   Krajewski, Stanislaw ^c   Renner, Stephen ^a,b   Fisher, Myrna ^a,b,c   Reed, John C ^a   Franke, Thomas F ^c   Lichtenstein, Alan ^a,d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BURNHAM INSTITUTE   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN KINASE B; WORTMANNIN;

ARTICLE; BONE MARROW; BONE MARROW BIOPSY; CELL GROWTH; CONTROLLED STUDY; ENZYME ACTIVATION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PLASMA CELL; PRIORITY JOURNAL; TUMOR CELL;

EID: 0035525792     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.9.2853     Document Type: Article

References (14)

1. Anderson K, Jones R, Morimoto C, Leavitt P, Barut B. Response patterns of purified myeloma cells to hematopoietic growth factors. Blood. 1989;73:1915-1922.
2. Lichtenstein A, Tu Y, Fady C, Vescio R, Berenson J. Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell Immunol. 1995;162:248-253.
3. Ogata A, Chauhan D, Urashima M, et al. IL-6 triggers multiple myeloma cell growth via the Ras dependent mitogen activated protein kinase cascade. J Immunol. 1997;159:2212-2220.
4. Chauhan D, Kharbanda S, Ogata A, et al. IL-6 inhibits fas-induced apoptosis and stress activated protein kinase activation in multiple myeloma cells. Blood. 1997;89:227-236.
5. Catlett-Falcone R, Landowski T, Oshiro MM, et al. Constitutive activation of STAT 3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999;10:105-115.
6. Tu Y, Gardner A, Lichtenstein A. The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses. Cancer Res. 2000;60:6763-6770.
7. Andjelkovic M, Alessi DR, Meier R, et al. Role of translocation in the activation and function of protein kinase B. J Biol Chem. 1997;272:31315-31324.
8. Franke TF, Yang S-I, Chan TO, et al. The protein kinase encoded by the AKT proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell. 1995;81:727-738.
9. Songyang Z, Baltimore D, Cantley LC, Kaplan DR, Franke T. Interleukin-3-dependent survival by the AKT protein kinase. Proc Natl Acad Sci U S A. 1997;94:11345-11350.
10. Kyle R, Monoclonal gammopathy of undetermined significance: natural history in 241 cases. Am J Med. 1978;64:814-823.
11. Alexanian R. Localized and indolent myeloma. Blood. 1980;56:521-529.
12. Tu Y, Renner S, Xu F-H, et al. BCL-X expression in multiple myeloma: possible indicator of chemoresistance. Cancer Res. 1998;58:256-262.
13. Xu F, Gardner A, Tu Y, Michl P, Prager D, Lichtenstein A. Multiple myeloma cells are protected against dexamethasone-induced apoptosis by insulin-like growth factors. Br J Hematol. 1997;97:429-437.
14. Hyun T, Yam A, Pece S, et al. Loss of PTEN expression leading to high AKT activation in human multiple myelomas. Blood. 2000;96:3560-3568.